Caligan Partners

Latest statistics and disclosures from Caligan Partners's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are LQDA, VRNA, EXEL, EOLS, ANIK, and represent 73.89% of Caligan Partners's stock portfolio.
  • Added to shares of these 5 stocks: YMAB (+$8.1M), AGIO, MLYS, EOLS, IMAB.
  • Reduced shares in these 7 stocks: Alimera Sciences (-$94M), LQDA (-$22M), BCRX (-$15M), VRNA (-$12M), ENTA (-$7.5M), OTLK, ANIK.
  • Sold out of its position in Alimera Sciences.
  • Caligan Partners was a net seller of stock by $-137M.
  • Caligan Partners has $316M in assets under management (AUM), dropping by -26.29%.
  • Central Index Key (CIK): 0001727492

Tip: Access up to 7 years of quarterly data

Positions held by Caligan Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Caligan Partners

Caligan Partners holds 12 positions in its portfolio as reported in the September 2024 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Liquidia Corporation Com New (LQDA) 25.7 $81M -21% 8.1M 10.00
 View chart
Verona Pharma Sponsored Ads (VRNA) 13.1 $41M -22% 1.4M 28.77
 View chart
Exelixis (EXEL) 12.6 $40M 1.5M 25.95
 View chart
Evolus (EOLS) 11.3 $36M 2.2M 16.20
 View chart
Anika Therapeutics (ANIK) 11.2 $35M 1.4M 24.70
 View chart
Agios Pharmaceuticals (AGIO) 8.2 $26M +12% 580k 44.43
 View chart
BioCryst Pharmaceuticals (BCRX) 6.2 $20M -43% 2.6M 7.60
 View chart
Y Mabs Therapeutics (YMAB) 5.0 $16M +105% 1.2M 13.15
 View chart
Mineralys Therapeutics (MLYS) 3.8 $12M +31% 981k 12.11
 View chart
I Mab Sponsored Ads (IMAB) 1.4 $4.3M +3% 3.5M 1.24
 View chart
Enanta Pharmaceuticals (ENTA) 1.1 $3.3M -69% 323k 10.36
 View chart
Outlook Therapeutics (OTLK) 0.5 $1.7M -36% 319k 5.34
 View chart

Past Filings by Caligan Partners

SEC 13F filings are viewable for Caligan Partners going back to 2022